Sun Pharma Advanced Research Company Ltd (SPARC) — shareholding pattern, promoter holding, financials and share price
About Sun Pharma Advanced Research Company Ltd (SPARC)
Sun Pharma Advanced Research Company Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SPARC and on the BSE under scrip code 532872. Its ISIN is INE232I01014.
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. [1]
Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage biopharmaceutical company focusing on drug creation and novel delivery systems. Their work spans new chemical entities and novel drug delivery systems (NDDS) for global markets.
SPARC engages in strategic licensing agreements, enabling Sun Pharma to commercialize drugs like Xelpros and Elepsia XR in the US market, showcasing the collaborative link between the two companies.
Listed peers in Pharmaceuticals: Strides Pharma Science Ltd, Sudeep Pharma Ltd, Sanofi India Ltd, Jeena Sikho Lifecare Ltd, FDC Ltd, Supriya Lifescience Ltd.
Valuation & Returns
10 Jul 2026At ₹264.6 a share on 10 Jul 2026, Sun Pharma Advanced Research Company Ltd (SPARC) was valued at a price-to-earnings ratio of 5.53x against an industry P/E of 36.41x and a price-to-book of 6.41x on a book value of ₹-6.69 per share as of Mar 2025. Solomo computes return on equity of 116.01% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 5.53x
- Industry P/E
- 36.41x
- P/B
- 6.41x
- EPS (TTM)
- ₹47.86
- Book value / share
- ₹-6.69
- ROE
- 116.01%
- ROA
- 462.9%
- Debt / equity
- 0.42x
- Dividend yield
- 0%
- 52-week range
- ₹108.2 – ₹289
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Sun Pharma Advanced Research Company Ltd (SPARC) reported revenue of ₹1,879 crore, net profit of ₹1,553 crore and earnings per share of ₹47.86. That compares with revenue of ₹72 crore and net profit of ₹-343 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1,853 crore and net profit ₹1,761 crore (consolidated).
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue (₹ cr) | 239 | 76 | 72 | 1,879 |
| Net profit (₹ cr) | -223 | -387 | -343 | 1,553 |
| EPS (₹) | -6.86 | -11.93 | -10.55 | 47.86 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -8.60% | -1.35% | -19.44% | -5.00% |
| Profit growth | - | - | - | 11.54% |
| Stock price CAGR | -3% | 0% | 4% | 54% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 65.67% of Sun Pharma Advanced Research Company Ltd (SPARC) (unchanged from the previous quarter), foreign institutional investors (FII) hold 3.9% and domestic institutional investors (DII) hold 0.09%. Market capitalisation was ₹8,587 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2010.
Largest disclosed public shareholders in Jun 2026: Sun Pharmaceutical Industries Key Employees Benefit Trust 3.18%, Lakshdeep Investments & Finance (P) Ltd. 1.86%, Paresh Mohanlal Parekh 1.13%, Vijay Mohanlal Parekh 1.13%, Enam Securities Private Limited 1.04%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 65.67% | - | 3.9% | 0.09% | 34.33% |
| Mar 2026 | 65.67% | - | 2.04% | 0.88% | 34.33% |
| Dec 2025 | 65.67% | - | 2.04% | 0.78% | 34.33% |
| Sep 2025 | 65.67% | - | 1.76% | 1.05% | 34.33% |
| Jun 2025 | 65.67% | - | 1.47% | 0.97% | 34.33% |
| Mar 2025 | 65.67% | - | 1.45% | 1.13% | 34.33% |
| Dec 2024 | 65.67% | - | 2.23% | 0.64% | 34.33% |
| Sep 2024 | 65.67% | 2.8% | 2.15% | 0.23% | 34.33% |